The demand for the development of therapeutic compounds targeting infectious diseases has surged over the past three years, particularly in response to the COVID-19 pandemic. This study aims to compile and analyze the pharmacological effects of metal-based organic complexes against a variety of viral infections, including COVID-19. A systematic review of the existing literature was conducted using databases such as Medline, Scopus, PubMed, and ScienceDirect. The methodology involved data gathering, summarization, and analysis of relevant studies. Antiviral activities are exhibited by metal complexes with various ligands, including hydrazones and thiosemi-carbazones (Pt(II), Pd(II), Ga(III), Pd(II), Co(III), Ni(II), Cu(II)), fluoroquinolones and quinolines (Pd(II)), phenylquinoline, phenylpyridine, tetrahydropyrimidines (Ag(I)), phenanthroline (Cu(II)), and valacyclovir (Cu(II)). Metal complexes containing Zn(II), Co(II), Cu(II), Ni(II), Mg(II), and Mn(II) have shown antiviral properties against DNA viruses, particularly herpes simplex viruses HSV-1 and HSV-2. HIV-inhibiting complexes have been identified with metals such as Au(II), Co(II), Cu(II), Fe(III), La(III), Mg(II), Ni(II), Pd(II), Pt(II), and Ru(II). In light of the persistent global spread of SARS-CoV-2, the development of effective treatments for COVID-19 remains a priority. Investigations into potential therapeutic agents for combating SARS-CoV-2 are focusing on compounds like auranofin and metal complexes of Cu(II), Ni(II), Mn(II), and Zn(II) combined with Coumarin.
Eurasian Academy of Medicine and Dentistry